<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544932</url>
  </required_header>
  <id_info>
    <org_study_id>PREFER-AF</org_study_id>
    <nct_id>NCT02544932</nct_id>
  </id_info>
  <brief_title>Pleotropic Effect of New Oral Anticoagulants</brief_title>
  <official_title>Prospective Randomized Study for Evaluating Vascular Protective Effects of New Oral Anticoagulants in High Risk Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including
      endothelial dysfunction of heart and vessel. This study was designed to determine the
      efficacy of NOAC therapy in the prevention of endothelial dysfunction and progression of
      atherosclerosis of AF subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The properties of oral, direct inhibitors of factor Xa (e.g. rivaroxaban) and thrombin (e.g.
      dabigatran) have been examined the haemostasis and thromboembolism management. Preclinical
      studies have provided evidences for the effects of direct factor Xa or thrombin inhibition
      beyond anticoagulation, including anti-inflammatory and protective activities in
      atherosclerotic plaque development . Therefore, this study evaluates the protective effects
      of NAOC with the reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements
      reflecting endothelial function by Endo-PAT2000 and intima-media thickness (IMT) of the
      carotid artery, which is used as a surrogate endpoint of atherosclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes in reactive hyperemia index (RHI)</measure>
    <time_frame>12months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>right and left maximum IMT of the common carotid artery (CCA)</measure>
    <time_frame>24months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>right and left mean IMT of the common carotid artery (CCA)</measure>
    <time_frame>24months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>24months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>dabigatran 110mg or 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After once enrolled, subjects will be randomized to dabigatran group. (110mg or 150mg twice a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ribaroxaban 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After once enrolled, subjects will be randomized to ribaroxaban group. (20mg once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After once enrolled, subjects will be randomized to warfarin group. (controlled by INR 2-3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran</intervention_name>
    <description>After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months</description>
    <arm_group_label>dabigatran 110mg or 150mg</arm_group_label>
    <other_name>pradaxa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribaroxaban</intervention_name>
    <description>After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.</description>
    <arm_group_label>ribaroxaban 20mg</arm_group_label>
    <other_name>xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.</description>
    <arm_group_label>warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CHA2DS2-VASc score above 2

        Exclusion Criteria:

          -  severe peripheral arterial disease (greater than a Fontaine IIb category)

          -  grade 4 or higher cerebral infarction on the Modified Rankin Scale

          -  proven coronary artery disease by coronary angiogram

          -  severe hepatic or renal dysfunction

          -  uncontrolled congestive heart failure

          -  uncontrolled hypertension or diabetes mellitus

          -  hematologic disorders

          -  allergy or hypersensitivity to the investigational drugs

          -  pregnant or lactating women or women wishing to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weon Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weon Kim, MD, PhD</last_name>
    <phone>82-2-958-8170</phone>
    <email>mylovekw@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin-Bae Kim, MD, PhD</last_name>
    <phone>82-2-958-8167</phone>
    <email>jinbbai@khu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kyung Hee University</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2015</study_first_submitted>
  <study_first_submitted_qc>September 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>September 7, 2015</last_update_submitted>
  <last_update_submitted_qc>September 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Weon Kim</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>anticoagulant</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>endothelium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

